Pharma Daily — October 5, 2026
One pipeline, five first-hand sources: 3 deals, 0 FDA approvals and 12 upcoming readouts, collected and charted without an LLM.
Pharma Daily
The daily brief, archived
A daily pharma/biotech finance brief built from first-hand sources only — SEC filings, FDA and trial registries, wire releases — with deal comps, readout calendars and market reaction, charted by an open pipeline. Every issue has an audio version and a video companion.
▶ video
Pharma Daily — September 17, 2026
One pipeline, five first-hand sources: 32 deals, 25 FDA approvals and 12 upcoming readouts, collected and charted without an LLM.
▶ video
Pharma Daily — September 9, 2026
Sep 8–9: 17 deal events, 0 FDA approvals, 12 queued readouts; Novartis's $12B Avidity bet hits a Phase 3 miss and Monte Rosa signs a $2.1B license.
▶ video
Pharma Daily — September 8, 2026
Sep 7–8: $14.6B in disclosed totals, zero FDA approvals, and Novartis's $12B Avidity buyout's lead asset fails Phase 3. Monte Rosa licenses VAV1 degraders to Novartis.
▶ video
Pharma Daily — September 7, 2026
Sep 6–7: zero deals, zero FDA approvals, and 12 Phase 2/3 readouts due within 90 days. The calendar, not the tape, is the story.
▶ video
Pharma Daily — September 5, 2026
Sep 4–5: Menarini/Gan & Lee $771M GLP-1 deal, NeuShen $80M financing, Novartis Lp(a) miss — China-originated assets took 100% of disclosed dollars.
▶ video
Pharma Daily — September 4, 2026
Sep 3–4: GSK-Hutchmed $110M upfront license, Medicus $1B ADC deal, ivonescimab Phase 3 OS win — China-originated assets dominated both deal flow and the tape.